{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:49Z","timestamp":1785517189715,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470152"],"award-info":[{"award-number":["82470152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170145"],"award-info":[{"award-number":["82170145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372659"],"award-info":[{"award-number":["82372659"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500203"],"award-info":[{"award-number":["82500203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400092"],"award-info":[{"award-number":["82400092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acquired resistance to Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), remains a critical challenge in lung adenocarcinoma. Here, we identify ATXN3, a deubiquitinating enzyme, as a driver of Osimertinib resistance and a predictor of poor patient survival. Osimertinib treatment dynamically upregulates ATXN3 transcription, which stabilizes USP25 through deubiquitination, activating an ATXN3-USP25-TRMT1 signaling cascade. This axis enhances TRMT1-mediated tRNA m\u00b2\n                    <jats:sub>2<\/jats:sub>\n                    G modifications, enabling selective translation of redox-regulating enzymes (e.g., GPX4, SOD2) that scavenge reactive oxygen species (ROS) and mitigate drug-induced oxidative stress. Genetic ablation of TRMT1 or pharmacological targeting of USP25 with the small-molecule inhibitor AZ1 disrupted this pathway, restored ROS accumulation, and re-sensitized resistant tumors to Osimertinib in patient-derived organoids and in vivo models. Our findings reveal tRNA epitranscriptomic reprogramming as a novel mechanism of EGFR-TKI resistance and position the ATXN3\/USP25\/TRMT1 axis as a therapeutically actionable target to overcome Osimertinib resistance in lung cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09039-8","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:14:13Z","timestamp":1782749653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TRMT1-mediated tRNA m22G modification drives Osimertinib resistance via the ATXN3\/USP25 axis in lung adenocarcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Jiaqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxinyi","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuofang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huishu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-5205","authenticated-orcid":false,"given":"Hu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-8757","authenticated-orcid":false,"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1383-0383","authenticated-orcid":false,"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"9039_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643\u201352.","journal-title":"Lancet Oncol"},{"key":"9039_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288\u201396.","journal-title":"J Clin Oncol"},{"key":"9039_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Osimertinib: first global approval. Drugs. 2016;76:263\u201373.","journal-title":"Drugs"},{"key":"9039_CR4","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u20139.","journal-title":"Ann Oncol"},{"key":"9039_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.","journal-title":"J Hematol Oncol"},{"key":"9039_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08074-0","volume":"10","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019;10:259.","journal-title":"Nat Commun"},{"key":"9039_CR7","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00432-020-03239-1","volume":"146","author":"Y Mu","year":"2020","unstructured":"Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T, et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol. 2020;146:2427\u201333.","journal-title":"J Cancer Res Clin Oncol"},{"key":"9039_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","volume":"20","author":"MJ Clague","year":"2019","unstructured":"Clague MJ, Urb\u00e9 S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol. 2019;20:338\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9039_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard RB. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021;28:423\u20136.","journal-title":"Cell Death Differ"},{"key":"9039_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","volume":"123","author":"SM Nijman","year":"2005","unstructured":"Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123:773\u201386.","journal-title":"Cell"},{"key":"9039_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01073-9","volume":"21","author":"L Wu","year":"2023","unstructured":"Wu L, Ou Z, Liu P, Zhao C, Tong S, Wang R, et al. ATXN3 promotes prostate cancer progression by stabilizing YAP. Cell Commun Signal. 2023;21:152.","journal-title":"Cell Commun Signal"},{"key":"9039_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2019.09.012","volume":"467","author":"H Zou","year":"2019","unstructured":"Zou H, Chen H, Zhou Z, Wan Y, Liu Z. ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4. Cancer Lett. 2019;467:19\u201328.","journal-title":"Cancer Lett"},{"key":"9039_CR13","doi-asserted-by":"publisher","first-page":"107415","DOI":"10.1016\/j.jbc.2024.107415","volume":"300","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wang S, Gao Q, Fang D. ATXN3 functions as a tumor suppressor through potentiating galectin-9-mediated apoptosis in human colon adenocarcinoma. J Biol Chem. 2024;300:107415.","journal-title":"J Biol Chem"},{"key":"9039_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4161\/cc.8.11.8739","volume":"8","author":"S Hussain","year":"2009","unstructured":"Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle. 2009;8:1688\u201397.","journal-title":"Cell Cycle"},{"key":"9039_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"9039_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41580-021-00342-0","volume":"22","author":"T Suzuki","year":"2021","unstructured":"Suzuki T. The expanding world of tRNA modifications and their disease relevance. Nat Rev Mol Cell Biol. 2021;22:375\u201392.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9039_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41422-018-0013-y","volume":"28","author":"T Pan","year":"2018","unstructured":"Pan T. Modifications and functional genomics of human transfer RNA. Cell Res. 2018;28:395\u2013404.","journal-title":"Cell Res"},{"key":"9039_CR18","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3390\/ijms19123738","volume":"19","author":"M Pereira","year":"2018","unstructured":"Pereira M, Francisco S, Varanda AS, Santos M, Santos MAS, Soares AR. Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease. Int J Mol Sci. 2018;19:3738.","journal-title":"Int J Mol Sci"},{"key":"9039_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83:89\u2013102.","journal-title":"Cancer Res"},{"key":"9039_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6428","volume":"13","author":"KR Zhang","year":"2021","unstructured":"Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med. 2021;13:eabg6428.","journal-title":"Sci Transl Med"},{"key":"9039_CR21","doi-asserted-by":"crossref","unstructured":"Cammas A, Herviou P, Dumas L, Millevoi S. Analysis of mRNA translation by polysome profiling. In: Dassi E, editor. Post-transcriptional gene regulation. New York, NY: Springer US; 2022.","DOI":"10.1007\/978-1-0716-1851-6_4"},{"key":"9039_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83469-6","volume":"11","author":"Z Sun","year":"2021","unstructured":"Sun Z, Tan J, Zhao M, Peng Q, Zhou M, Zuo S, et al. Integrated genomic analysis reveals regulatory pathways and dynamic landscapes of the tRNA transcriptome. Sci Rep. 2021;11:5226.","journal-title":"Sci Rep"},{"key":"9039_CR23","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"9039_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"9039_CR25","doi-asserted-by":"publisher","first-page":"e00214","DOI":"10.1128\/MCB.00214-17","volume":"37","author":"JM Dewe","year":"2017","unstructured":"Dewe JM, Fuller BL, Lentini JM, Kellner SM, Fu D. TRMT1-Catalyzed tRNA modifications are required for redox homeostasis to ensure proper cellular proliferation and oxidative stress survival. Mol Cell Biol. 2017;37:e00214\u201317.","journal-title":"Mol Cell Biol"},{"key":"9039_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115092","volume":"44","author":"K Zhang","year":"2025","unstructured":"Zhang K, Manning AC, Lentini JM, Howard J, Dalwigk F, Maroofian R, et al. Human TRMT1 and TRMT1L paralogs ensure the proper modification state, stability, and function of tRNAs. Cell Rep. 2025;44:115092.","journal-title":"Cell Rep"},{"key":"9039_CR27","doi-asserted-by":"publisher","first-page":"e1002603","DOI":"10.1371\/journal.pgen.1002603","volume":"8","author":"W Qian","year":"2012","unstructured":"Qian W, Yang JR, Pearson NM, Maclean C, Zhang J. Balanced codon usage optimizes eukaryotic translational efficiency. PLoS Genet. 2012;8:e1002603.","journal-title":"PLoS Genet"},{"key":"9039_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/BCJ20240017","volume":"481","author":"A Potapenko","year":"2024","unstructured":"Potapenko A, Davidson JM, Lee A, Laird AS. The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases. Biochem J. 2024;481:461\u201380.","journal-title":"Biochem J"},{"key":"9039_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.pan.2023.06.011","volume":"23","author":"X Wu","year":"2023","unstructured":"Wu X, Zhang X, Liu P, Wang Y. Involvement of Ataxin-3 (ATXN3) in the malignant progression of pancreatic cancer via deubiquitinating HDAC6. Pancreatology. 2023;23:630\u201341.","journal-title":"Pancreatology"},{"key":"9039_CR30","first-page":"4213","volume":"19","author":"D Li","year":"2019","unstructured":"Li D, Zhang T, Lai J, Zhang J, Wang T, Ling Y, et al. MicroRNA-25\/ATXN3 interaction regulates human colon cancer cell growth and migration. Mol Med Rep. 2019;19:4213\u201321.","journal-title":"Mol Med Rep"},{"key":"9039_CR31","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1038\/onc.2013.512","volume":"33","author":"JJ Sacco","year":"2014","unstructured":"Sacco JJ, Yau TY, Darling S, Patel V, Liu H, Urb\u00e9 S, et al. The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 2014;33:4265\u201372.","journal-title":"Oncogene"},{"key":"9039_CR32","doi-asserted-by":"publisher","first-page":"zcae012","DOI":"10.1093\/narcan\/zcae012","volume":"6","author":"AM A\u00f1azco-Guenkova","year":"2024","unstructured":"A\u00f1azco-Guenkova AM, Miguel-L\u00f3pez B, Monteagudo-Garc\u00eda \u00d3, Garc\u00eda-V\u00edlchez R, Blanco S. The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues. NAR Cancer. 2024;6:zcae012.","journal-title":"NAR Cancer"},{"key":"9039_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221134735","volume":"16","author":"N Nie","year":"2022","unstructured":"Nie N, Li J, Zhang J, Dai J, Liu Z, Ding Z, et al. First-line Osimertinib in patients with EGFR-mutated non-small cell lung cancer: effectiveness, resistance mechanisms, and prognosis of different subsequent treatments. Clin Med Insights Oncol. 2022;16:11795549221134735.","journal-title":"Clin Med Insights Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09039-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:05:35Z","timestamp":1785513935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09039-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9039"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09039-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8455091\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Ethics Committee of Shanghai Chest Hospital (Approval number KS24041).","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All the authors have read and approved the final manuscript for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"660"}}